Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Public ClinicalTrials.gov record NCT02284893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.
Study identification
- NCT ID
- NCT02284893
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 461 participants
Conditions and interventions
Conditions
Interventions
- Saxagliptin Drug
- Dapagliflozin Drug
- Sitagliptin Drug
- Placebo matching with Saxagliptin Drug
- Placebo matching with Dapagliflozin Drug
- Placebo matching with Sitagliptin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2014
- Primary completion
- Sep 19, 2016
- Completion
- Sep 19, 2016
- Last update posted
- May 31, 2018
2014 – 2016
United States locations
- U.S. sites
- 40
- U.S. states
- 15
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mesa | Arizona | 85206 | — |
| Research Site | Mesa | Arizona | 85213 | — |
| Research Site | Phoenix | Arizona | 85020 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Huntington Beach | California | 92648 | — |
| Research Site | Huntington Park | California | 90255 | — |
| Research Site | Lomita | California | 90717 | — |
| Research Site | Los Angeles | California | 90057 | — |
| Research Site | Northridge | California | 91325 | — |
| Research Site | Norwalk | California | 90650 | — |
| Research Site | Paramount | California | 90723 | — |
| Research Site | Sacramento | California | 95823 | — |
| Research Site | Tarzana | California | 91356 | — |
| Research Site | Tustin | California | 92780 | — |
| Research Site | Golden | Colorado | 80401 | — |
| Research Site | Coral Gables | Florida | 33134 | — |
| Research Site | Kissimmee | Florida | 34744 | — |
| Research Site | Miami | Florida | 33015 | — |
| Research Site | Miami | Florida | 33135 | — |
| Research Site | Miami | Florida | 33174 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Palm Harbor | Florida | 34684 | — |
| Research Site | Pembroke Pines | Florida | 33026 | — |
| Research Site | Chicago | Illinois | 60634 | — |
| Research Site | Council Bluffs | Iowa | 51503 | — |
| Research Site | Crestview Hills | Kentucky | 41017 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Morehead City | North Carolina | 28557 | — |
| Research Site | Salisbury | North Carolina | 28144 | — |
| Research Site | Norman | Oklahoma | 73069 | — |
| Research Site | Columbia | South Carolina | 29204 | — |
| Research Site | Bristol | Tennessee | 37620 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Houston | Texas | 77081 | — |
| Research Site | North Richland Hills | Texas | 76180 | — |
| Research Site | Pasadena | Texas | 77504 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Manassas | Virginia | 20110 | — |
| Research Site | Suffolk | Virginia | 23452 | — |
| Research Site | Kenosha | Wisconsin | 53142 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02284893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02284893 live on ClinicalTrials.gov.